Free Trial
NASDAQ:GANX

Gain Therapeutics Q2 2026 Earnings Results & Report

Gain Therapeutics logo
$1.04 -0.04 (-3.70%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$1.06 +0.02 (+1.73%)
As of 11/13/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gain Therapeutics beat analyst earnings expectations in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$0.11 versus the -$0.1380 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Gain Therapeutics EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.1380
Beat/Miss
Beat by +$0.0280
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Gain Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$33 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Gain Therapeutics Q2 2026 Earnings FAQ

Gain Therapeutics (NASDAQ:GANX) reported earnings of -$0.11 per share for Q2 2026, beating the consensus estimate of -$0.1380. The report was announced on Tuesday, August 11, 2026.

Gain Therapeutics Earnings Headlines

Gain Therapeutics Q3 Loss Narrows
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Gain Therapeutics (GANX) Projected to Announce Earnings on Wednesday
See More Gain Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gain Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gain Therapeutics and other key companies, straight to your email.

About Gain Therapeutics

Gain Therapeutics (NASDAQ:GANX) is a biotechnology company developing small-molecule treatments for neurological and other diseases linked to dysfunctional proteins. Its research focuses on conditions for which existing therapies may not address the underlying protein dysfunction.

The company uses its discovery platform, which combines computational methods and structural biology, to identify previously unexplored binding sites on proteins. It aims to develop compounds that bind at these sites and help restore protein function.

Gain Therapeutics’ lead program, GT-02287, is an oral investigational therapy being developed for Parkinson’s disease, including disease associated with GBA1 mutations. The company is also pursuing drug-discovery programs for other neurological and lysosomal disorders.

View Gain Therapeutics Profile